English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 August 2022, 11:30 HKT/SGT
Share:
Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
Data results will be available in Q1 2023

Gaithersburg, MD, USA and Suzhou BioBay, China, Aug 19, 2022 - (ACN Newswire) -  Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has dosed the first patient in a Phase I/II clinical study of STP705, the Company's leading siRNA (small interfering RNA) drug candidate, for the treatment of patients with facial squamous cell skin cancer in situ (isSCC).

The open label, dose escalation study is designed to evaluate the safety, tolerability, and efficacy of various doses of STP705 administered by intralesional injection and to determine the recommended dose. The study will also analyze biomarkers common to isSCC formation pathways, including TGF-beta1 and COX-2. The primary endpoint is to determine the number of patients with histological clearance (HC) of facial isSCC lesions at the end of treatment with STP705. HC is defined as the absence of detectable evidence of the isSCC tumor cell nests as determined by central pathology review. A total of 30 patients, divided into three cohorts of 10 patients each, will receive a given dose once per week for six weeks. Cohort A will receive a 30 ug dose, Cohort B a 60 ug dose, and Cohort C a 90 ug dose.

"We expect that the study of STP705 as a treatment for facial isSCC to yield positive results given previous studies of STP705 that have shown to be safe and effective as a cancer treatment," said Dr. Patrick Lu, founder, Chairman of the Board, Executive Director, President and CEO of Sirnaomics. "Our drug has the potential to offer millions of patients with these non-melanoma facial lesions a non-surgical, non-invasive alternative to traditional lesion removal."

"With surgical removal being the only available treatment for isSCC currently, patients have normally found the results to be painful and aesthetically unpleasing on the face. By dosing our first patient in this Phase I/II study, we can begin to evaluate the safety and effectiveness of STP705 in eradicating these cancerous lesions," said Michael Molyneaux M.D., Executive Director and Chief Medical Officer of Sirnaomics. "Formulating this clinical trial as a dose escalation study also gives us the opportunity to determine which dose is the best suited in removing the cancer without adverse events."

The study started in the United States in August 2022, and is expected to be completed in Q1 2023. Additional information about this clinical trial is available at clinicaltrials.gov using the identifier: NCT05421013.

About STP705
Sirnaomics' leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-beta1 and COX2 gene expression. The product candidate has received multiple IND approvals from both the U.S. Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA), including treatments of cholangiocarcinoma, non-melanoma skin cancer and hypertrophic scar. STP705 has also received Orphan Drug Designation for treatment of cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC). STP705 is currently in seven clinical trials for different indications: a Phase IIb for squamous cell carcinoma in situ (isSCC), a Phase II for basal cell carcinoma (BCC), a Phase I/II for keloid scarring, a Phase I/II for hypertrophic scar (HTS), a Phase I/II for facial isSCC, a Phase I for liver cancer (basket), and a Phase I for medical cosmetology treatment.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Michael Molyneaux, MD, MBA
Executive Director and Chief Medical Officer, Sirnaomics
Email: MichaelMolyneaux@sirnaomics.com

Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com


Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
BPipe Corporation, a Joint Venture Partner of Biopipe Global USA, enters into Agreement with Major Global Food Company to Install 10 m3/day Biopipe Biological Sewage Wastewater Treatment Plant  
Sept 27, 2022 20:00 HKT/SGT
SNS Network Technology Posts 42.4% Rise in Net Profit for 2Q FY2023  
Sept 27, 2022 19:00 HKT/SGT
MetaBoundless Hosts First-ever Avatar Concert in the Metaverse  
Sept 27, 2022 18:17 HKT/SGT
Metafluence Announces the Usage of Hyper-realistic Metahumans in the Metaverse  
Sept 27, 2022 16:00 HKT/SGT
DENSO Expands Vision Sensor Detection Angle for Subaru Legacy Outback, Crosstrek Models  
Tuesday, September 27, 2022 1:33:00 PM
Solar Energy Future MALAYSIA 2022 is on Fire  
Sept 27, 2022 09:00 HKT/SGT
Focally unveils the world's first Full colour Micro-led based true AR glasses with fully see-through display and USound MEMS speakers' technology  
Sept 27, 2022 09:00 HKT/SGT
Tech-titans unite to redefine the future of Cloud and Sustainable Data Centers in Dubai  
Sept 26, 2022 23:30 HKT/SGT
Less Than a Month to go for Jordan's Largest Tech Expo for Start-ups  
Sept 26, 2022 23:00 HKT/SGT
Hitachi Astemo Receives EV e-Axle Orders from Honda, and will Further Expand its Electrification Business  
Monday, September 26, 2022 7:25:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575